Monitor proxy vote outcome on June 9; DOMA's 3 nominees are unlikely to gain seats given management's shareholder outreach (97.4% of shares contacted) and recent operational momentum. If DOMA loses, near-term stability supports the stock; a surprise win would introduce strategic uncertainty.
PCRX drugs
PCRX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 28 $23.68entry
- T+1 · 6mo ago −1.94%α −2.18% · $23.22
- T+5 · 6mo ago −4.27%α −4.58% · $22.67
- T+20 · 5mo ago +6.59%α +9.73% · $25.24
- T+60 · 3mo ago +4.18%α +2.45% · $24.67
Price Chart
How similar events traded
Executive Summary
Pacira BioSciences issued a DEFA14A letter to stockholders ahead of its June 9, 2026 Annual Meeting, urging support for its three board nominees and rebutting activist DOMA Perpetual's proxy contest. The letter highlights record 2025 revenue of $726.4M, GAAP net income of $7.0M ($0.16/share), and EXPAREL volume growth of 6.2%, while arguing DOMA's nominees lack relevant experience.
Key Financial Metrics
Key Facts
- Annual Meeting scheduled for June 9, 2026; three board seats contested by DOMA Perpetual nominees.
- Pacira reports 2025 record total revenues of $726.4M and GAAP net income of $7.0M ($0.16 per share).
- EXPAREL year-over-year volume growth of 6.2% in 2025, accelerating to 8% in H2 2025.
- Management and board have met with DOMA 17 times since September 2023 but determined its nominees lack relevant experience.
- Stock price up ~31% since announcement of 5x30 strategy (Jan 2025 to May 2026).
- EXPREL settlement provides full exclusivity into 2030 with gradual capped transition through 2039.
Financial Impact
Record $726.4M revenue and $7.0M GAAP net income in 2025
Risk Factors
- Activist proxy contest could distract management or force suboptimal capital allocation changes.
- EXPAREL volume growth, while improving, remains below 10% annual target.
- Patent litigation over EXPAREL could re-emerge despite recent settlement.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001628280-26-038528 |
| Document: 0001628280-26-038528-index-headers.html | 0001628280-26-038528 |
| Document: 0001628280-26-038528-index.html | 0001628280-26-038528 |
| Document: 0001628280-26-038528.txt | 0001628280-26-038528 |
Track record
29 reports on PCRX
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +42.26% at T+60 after the Aug 6, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Bearish 6/10 Entry $36.46 Now $36.48 −0.05% settles Dec 14
- Nov 12, 20264d ago SC TO-T/A Mixed 7/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
- Nov 12, 20264d ago SC 14D-9/A Neutral 3/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $36.43 Now $36.48 +0.14% settles Dec 7
- Nov 3, 202613d ago SC 14D-9/A Neutral 3/10 Entry $36.40 Now $36.48 +0.22% settles Dec 3
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 30, 202617d ago SC 14D-9 Bullish 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 30, 202617d ago SC TO-T Mixed 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 13, 20264w ago SC 13D/A Bearish 7/10 Entry $36.40 to $36.46 Now $36.48 −0.22% ▼ −0.16% −1.44% vs SPY
- Oct 8, 20265w ago SC TO-C Bullish 7/10 Entry $36.31 to $36.43 Now $36.48 +0.47% ▲ +0.33% +5.89% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers